These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 22769575

  • 1. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI.
    Xu Q, Yin J, Si LY.
    Int J Cardiol; 2013 Jan 20; 162(3):210-9. PubMed ID: 22769575
    [Abstract] [Full Text] [Related]

  • 2. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
    Montalescot G, Borentain M, Payot L, Collet JP, Thomas D.
    JAMA; 2004 Jul 21; 292(3):362-6. PubMed ID: 15265852
    [Abstract] [Full Text] [Related]

  • 3. Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study.
    Ohlmann P, Reydel P, Jacquemin L, Adnet F, Wolf O, Bartier JC, Weiss A, Lapostolle F, Gaultier C, Salengro E, Benamer H, Guyon P, Chevalier B, Catan S, Ecollan P, Chouihed T, Angioi M, Zupan M, Bronner F, Bareiss P, Steg G, Montalescot G, Monassier JP, Morel O.
    Circ Cardiovasc Interv; 2012 Feb 01; 5(1):69-76, S1. PubMed ID: 22319064
    [Abstract] [Full Text] [Related]

  • 4. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R, Sardar P, Amin H, Swaminathan RV, Kim LK, Chatterjee S, Feldman DN.
    Am J Cardiol; 2014 Jul 15; 114(2):250-9. PubMed ID: 24890986
    [Abstract] [Full Text] [Related]

  • 5. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
    Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.
    J Am Coll Cardiol; 2010 Aug 03; 56(6):463-9. PubMed ID: 20670755
    [Abstract] [Full Text] [Related]

  • 6. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
    Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA.
    Catheter Cardiovasc Interv; 2006 Aug 03; 68(2):218-24. PubMed ID: 16817177
    [Abstract] [Full Text] [Related]

  • 7. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
    De Luca G, Marino P.
    Am J Emerg Med; 2009 Jul 03; 27(6):683-90. PubMed ID: 19751625
    [Abstract] [Full Text] [Related]

  • 8. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
    Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K, Taddei T, Tarducci R, Cosmi F, Baldassarre S, Burali A.
    J Am Coll Cardiol; 2006 Feb 07; 47(3):522-8. PubMed ID: 16458130
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Sinno MC, Khanal S, Al-Mallah MH, Arida M, Weaver WD.
    Am Heart J; 2007 Apr 07; 153(4):579-86. PubMed ID: 17383297
    [Abstract] [Full Text] [Related]

  • 10. Upstream vs deferred administration of small-molecule glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: insights from randomized clinical trials.
    Dong L, Zhang F, Shu X.
    Circ J; 2010 Aug 07; 74(8):1617-24. PubMed ID: 20571247
    [Abstract] [Full Text] [Related]

  • 11. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
    Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S.
    Can J Cardiol; 2007 Oct 07; 23(12):963-70. PubMed ID: 17932572
    [Abstract] [Full Text] [Related]

  • 12. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.
    Circ Cardiovasc Interv; 2009 Jun 07; 2(3):230-6. PubMed ID: 20031720
    [Abstract] [Full Text] [Related]

  • 13. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).
    Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP.
    J Am Coll Cardiol; 2007 Apr 10; 49(14):1517-24. PubMed ID: 17418289
    [Abstract] [Full Text] [Related]

  • 14. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF.
    Coron Artery Dis; 2008 Jun 10; 19(4):271-7. PubMed ID: 18480672
    [Abstract] [Full Text] [Related]

  • 15. Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from randomized clinical trials.
    Dong L, Zhang F, Shu X.
    J Cardiovasc Pharmacol Ther; 2010 Jun 10; 15(2):135-44. PubMed ID: 20435991
    [Abstract] [Full Text] [Related]

  • 16. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.
    Rakowski T, Siudak Z, Dziewierz A, Birkemeyer R, Legutko J, Mielecki W, Depukat R, Janzon M, Stefaniak J, Zmudka K, Dubiel JS, Partyka L, Dudek D.
    Am Heart J; 2009 Oct 10; 158(4):569-75. PubMed ID: 19781416
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 10; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 18. Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study.
    Tousek P, Rokyta R, Tesarova J, Pudil R, Belohlavek J, Stasek J, Rohac F, Widimsky P.
    Acute Card Care; 2011 Sep 10; 13(3):116-22. PubMed ID: 21526919
    [Abstract] [Full Text] [Related]

  • 19. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T, Boersma E, Ruzyllo W, Widimsky P, Ohman EM, Armstrong PW, Wallentin L, Simoons ML, GUSTO IV-ACS Investigators.
    Am Heart J; 2004 May 10; 147(5):865-73. PubMed ID: 15131544
    [Abstract] [Full Text] [Related]

  • 20. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    Young JJ, Kereiakes DJ.
    J Invasive Cardiol; 2002 Jul 10; 14(7):404-10. PubMed ID: 12082194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.